CoChat

Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease

Open access
Berk, Camryn, Sabbagh, Marwan N. · 2013 · Drugs & Aging
Cited by 63

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

To date, symptomatic medications prevail as the mainstay of treatment options for Alzheimer’s disease (AD). There have been tremendous investments made to increase the numbers of drugs approved and the targets engaged, in an effort to alter the disease course or pathophysiology of AD. Unfortunately, almost all studies have not met expectations and no new drug (beyond medical foods) has been approved for the treatment of AD in the last decade. This review is a comparison of novel AD therapies in the late phases of clinical testing, including recent high-profile clinical failures, and agents in development with relatively unexplored mechanisms of action, with a focus on their potential as therapeutic agents and their proposed advantages over the treatments currently in use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40266-013-0108-6

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 63

Metadata

Authors
Berk, C., & Sabbagh, M. N.
Venue
Drugs & Aging
Published
2013-08-14
Volume
30
Issue
10
Pages
783-792
ISSN
  • 1170-229X (ISSN-L)
  • 1179-1969
OpenAlex
W2079007822
Cited by
63
References
14
FWCI
4.49
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease. https://app.cochat.ai/papers/10.1007/s40266-013-0108-6
The paper
Berk, C., & Sabbagh, M. N. (2013). Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease. Drugs & Aging. https://doi.org/10.1007/s40266-013-0108-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.